← Open Payments lookup

NPI 1639444011: Open Payments

NPI 1639444011. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$962 in 27 payments from 12 companies in 2025. Trend: 2023 $3,479 · 2024 $1,700 · 2025 $962

Food & beverage: $962
CompanyPaymentsAmount
Regeneron Healthcare Solutions, Inc.5$224
AstraZeneca Pharmaceuticals LP2$165
Galderma Laboratories, L.P.3$151
CSL Behring4$93
Takeda Pharmaceuticals U.S.A., Inc.2$59
GlaxoSmithKline, LLC.2$48
Octapharma USA, Inc.2$48
ARS Pharmaceuticals Operations, Inc.2$45
Optinose US, Inc.2$44
Blueprint Medicines Corporation1$41

Products named: DUPIXENT, NEMLUVIO, FASENRA, Haegarda, CUVITRU, TRELEGY ELLIPTA, CUTAQUIG, NEFFY.